

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
0701	Sr89 strontium	K		\$4,156.573	.	\$831.32			*	
0726	Dexrazoxane HCl injection	K		\$113.897	.	\$22.78			*	
0731	Sargramostim injection	K		\$58.311	.	\$11.33	\$11.33		*	Inflation-adjusted coinsurance
0736	Amphotericin b liposome inj	K		\$27.871	.	\$5.58			*	
0738	Rasburicase	K		\$357.364	.	\$71.48			*	
0752	Dactinomycin injection	K		\$594.546	.	\$118.91			*	
0759	Naltrexone, depot form	K		\$3.940	.	\$0.79	\$0.79		*	Inflation-adjusted coinsurance
0800	Leuprolide acetate	K		\$1,543.516	.	\$299.08	\$299.08		*	Inflation-adjusted coinsurance
0802	Etoposide oral	K		\$77.388	.	\$15.48			*	
0807	Aldesleukin injection	K		\$3,628.260	.	\$725.66			*	
0810	Goserelin acetate implant	K		\$613.565	.	\$122.72			*	
0812	Carbustine injection	K		\$410.962	.	\$82.20			*	
0820	Daunorubicin injection	K		\$45.622	.	\$9.13			*	
0825	Nelarabine injection	K		\$128.994	.	\$25.80			*	
0836	Interferon alfa-2b inj	K		\$32.574	.	\$6.52			*	
0840	Inj melpha hydroch nos 50 mg	K		\$154.188	.	\$30.84			*	
0843	Pegaspargase injection	K		\$25,762.460	.	\$4,927.99	\$1,600.00		*	Inflation-adjusted coinsurance. Copayme
0844	Pentostatin injection	K		\$2,387.725	.	\$450.85	\$450.85		*	Inflation-adjusted coinsurance
0850	Streptozocin injection	K		\$370.184	.	\$74.04			*	
0851	Thiotepa injection	K		\$259.563	.	\$51.92			*	
0856	Porfimer sodium injection	K		\$22,490.020	.	\$4,498.01	\$1,600.00		*	Copayments capped at inpatient deducti
0858	Inj cladribine	K		\$18.296	.	\$3.66			*	
0864	Mitoxantrone hydrochl	K		\$29.060	.	\$5.82			*	
0874	Synvisc or synvisc-one	K		\$9.617	.	\$1.93			*	
0875	Euflexxa inj per dose	K		\$131.420	.	\$26.29			*	
0877	Orthovisc inj per dose	K		\$117.377	.	\$23.48			*	
0887	Azathioprine parenteral	K		\$240.196	.	\$48.04			*	
0890	Lymphocyte immune globulin	K		\$2,989.437	.	\$540.35	\$540.35		*	Inflation-adjusted coinsurance
0901	Alpha 1 proteinase inhibitor	K		\$4.878	.	\$0.98			*	
0902	Injection, onabotulinumtoxinA	K		\$6.394	.	\$1.28			*	
0903	Cytomegalovirus imm IV /vial	K		\$1,814.195	.	\$347.84	\$347.84		*	Inflation-adjusted coinsurance
0925	Factor viii	K		\$1.029	.	\$0.21			*	
0927	Factor viii recombinant	K		\$1.506	.	\$0.31			*	
0928	Factor ix complex	K		\$1.615	.	\$0.33			*	
0929	Anti-inhibitor	K		\$2.232	.	\$0.45			*	
0931	Factor IX non-recombinant	K		\$1.297	.	\$0.26	\$0.26		*	Inflation-adjusted coinsurance
0932	Factor ix recombinant nos	K		\$1.756	.	\$0.36			*	
0943	Octagam injection	K		\$44.118	.	\$8.83			*	
0944	Gammagard liquid injection	K		\$46.031	.	\$9.21			*	
0946	Hepagam b im injection	K		\$66.257	.	\$13.26			*	
0947	Flebogamma injection	K		\$56.116	.	\$7.95	\$7.95		*	Inflation-adjusted coinsurance
0948	Gamunex-C/Gammaked	K		\$50.640	.	\$10.13			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
0961	Albumin (human),5%, 50ml	K		\$10.615	.	\$2.13			*	
0963	Albumin (human), 5%, 250 ml	K		\$53.077	.	\$10.62			*	
0964	Albumin (human), 25%, 20 ml	K		\$21.231	.	\$4.25			*	
0965	Albumin (human), 25%, 50ml	K		\$53.077	.	\$10.62			*	
1015	Injection glatiramer acetate	K		\$151.431	.	\$30.29			*	
1064	I131 iodide cap, rx	K		\$23.730	.	\$4.75			*	
1083	Adalimumab injection	K		\$1,834.494	.	\$361.77	\$361.77		*	Inflation-adjusted coinsurance
1138	Hepagam b intravenous, inj	K		\$66.257	.	\$13.26			*	
1139	Protein c concentrate	K		\$15.112	.	\$3.03			*	
1150	I131 iodide sol, rx	K		\$22.710	.	\$4.55			*	
1168	Inj, temsirolimus	K		\$33.637	.	\$6.73			*	
1178	Busulfan injection	K		\$1.383	.	\$0.28			*	
1203	Verteporfin injection	K		\$11.416	.	\$2.29			*	
1207	Octreotide injection, depot	K		\$208.117	.	\$41.63			*	
1213	Antihemophilic viii/vwf comp	K		\$1.216	.	\$0.25			*	
1214	Inj IVIG privigen 500 mg	K		\$47.992	.	\$9.60			*	
1232	Mitomycin injection	K		\$79.024	.	\$15.81			*	
1235	Valrubicin injection	K		\$1,391.799	.	\$278.36			*	
1236	Inj levoleucovorin nos 0.5mg	K		\$0.039	.	\$0.01			*	
1237	Inj iron dextran	K		\$17.176	.	\$3.44			*	
1263	Antithrombin iii injection	K		\$3.350	.	\$0.67			*	
1268	Xyntha inj	K		\$1.376	.	\$0.28			*	
1274	Edetate calcium disodium inj	K		\$5,708.594	.	\$1,141.72			*	
1281	Bevacizumab injection	K		\$1.839	.	\$0.37			*	
1289	AbobotulinumtoxinA	K		\$8.246	.	\$1.65			*	
1295	Sm 153 lexidronam	K		\$17,259.853	.	\$3,451.98	\$1,600.00		*	Copayments capped at inpatient deducti
1296	Degarelix injection	K		\$4.194	.	\$0.84			*	
1297	Ferumoxitol, non-esrd	K		\$0.503	.	\$0.11			*	
1311	Canakinumab injection	K		\$121.513	.	\$24.31			*	
1312	Hizentra injection	K		\$12.803	.	\$2.57			*	
1327	Imiglucerase injection	K		\$44.250	.	\$8.86			*	
1340	Collagenase, clost hist inj	K		\$65.148	.	\$12.45	\$12.45		*	Inflation-adjusted coinsurance
1341	Amobarbital 125 MG inj	K		\$171.170	.	\$34.24			*	
1352	Wilate injection	K		\$1.259	.	\$0.26			*	
1353	Belimumab injection	K		\$50.927	.	\$10.19			*	
1408	Cyclophosphamide 100 MG inj	K		\$17.087	.	\$3.42			*	
1413	Lumizyme injection	K		\$194.915	.	\$38.99			*	
1415	Glassia injection	K		\$5.311	.	\$1.07			*	
1417	Gel-one	K		\$516.727	.	\$103.35			*	
1420	Aflibercept injection	K		\$875.670	.	\$175.14			*	
1421	Imported lipodox inj	K		\$424.100	.	\$84.83			*	
1426	Eribulin mesylate injection	K		\$128.777	.	\$25.76			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
1431	Centruroides immune f(ab)	K		\$5,208.664	.	\$1,041.74			*	
1433	Calcitonin salmon injection	K		\$1,366.440	.	\$273.29			*	
1440	Inj desmopressin acetate	K		\$7.271	.	\$1.46			*	
1442	Non-HEU TC-99M add-on/dose	K		\$10.000	.	\$2.00			*	
1443	Icatibant injection	K		\$228.607	.	\$45.73			*	
1446	Visualization adjunct	K		\$7.723	.	\$1.55			*	
1458	Phentolaine mesylate inj	K		\$458.182	.	\$91.64			*	
1466	Inj, vincristine sul lip 1mg	K		\$3,420.781	.	\$684.16			*	
1467	Factor ix recombinan rixubis	K		\$1.614	.	\$0.33			*	
1468	Inj Aripiprazole Ext Rel 1mg	K		\$6.723	.	\$1.35			*	
1469	Inj filgrastim excl biosimil	K		\$0.985	.	\$0.20			*	
1471	Injection, Pertuzumab, 1 mg	K		\$15.366	.	\$3.08			*	
1472	Inj beta interferon im 1 mcg	K		\$53.147	.	\$10.63			*	
1474	Certolizumab pegol inj 1mg	K		\$5.073	.	\$1.02			*	
1475	Golimumab for iv use 1mg	K		\$13.287	.	\$2.66			*	
1476	Obinutuzumab inj	K		\$70.546	.	\$14.11			*	
1478	Inj human fibrinogen con nos	K		\$1.383	.	\$0.28			*	
1480	Elosulfase alfa, injection	K		\$280.126	.	\$56.03			*	
1482	Darbepoetin alfa, esrd use	K		\$2.936	.	\$0.59			*	
1485	Ferumoxytol, esrd use	K		\$0.503	.	\$0.11			*	
1486	Factor ix fc fusion recomb	K		\$3.460	.	\$0.70			*	
1488	Injection, ramucirumab	K		\$68.870	.	\$13.78			*	
1489	Injection, vedolizumab	K		\$22.677	.	\$4.54			*	
1490	Inj pembrolizumab	K		\$54.811	.	\$10.97			*	
1491	New Technology - Level 1A (\$0-\$10)	S		\$5.00	.	\$1.00				
1492	New Technology - Level 1B (\$11-\$20)	S		\$15.50	.	\$3.10				
1493	New Technology - Level 1C (\$21-\$30)	S		\$25.50	.	\$5.10				
1494	New Technology - Level 1D (\$31-\$40)	S		\$35.50	.	\$7.10				
1495	New Technology - Level 1E (\$41-\$50)	S		\$45.50	.	\$9.10				
1496	New Technology - Level 1A (\$0-\$10)	T		\$5.00	.	\$1.00				
1497	New Technology - Level 1B (\$11-\$20)	T		\$15.50	.	\$3.10				
1498	New Technology - Level 1C (\$21-\$30)	T		\$25.50	.	\$5.10				
1499	New Technology - Level 1D (\$31-\$40)	T		\$35.50	.	\$7.10				
1500	New Technology - Level 1E (\$41-\$50)	T		\$45.50	.	\$9.10				
1502	New Technology - Level 2 (\$51 - \$100)	S		\$75.50	.	\$15.10				
1503	New Technology - Level 3 (\$101 - \$200)	S		\$150.50	.	\$30.10				
1504	New Technology - Level 4 (\$201 - \$300)	S		\$250.50	.	\$50.10				
1505	New Technology - Level 5 (\$301 - \$400)	S		\$350.50	.	\$70.10				
1506	New Technology - Level 6 (\$401 - \$500)	S		\$450.50	.	\$90.10				
1507	New Technology - Level 7 (\$501 - \$600)	S		\$550.50	.	\$110.10				
1508	New Technology - Level 8 (\$601 - \$700)	S		\$650.50	.	\$130.10				
1509	New Technology - Level 9 (\$701 - \$800)	S		\$750.50	.	\$150.10				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
1510	New Technology - Level 10 (\$801 - \$900)	S		\$850.50	.	\$170.10				
1511	New Technology - Level 11 (\$901 - \$1000)	S		\$950.50	.	\$190.10				
1512	New Technology - Level 12 (\$1001 - \$1100)	S		\$1,050.50	.	\$210.10				
1513	New Technology - Level 13 (\$1101 - \$1200)	S		\$1,150.50	.	\$230.10				
1514	New Technology - Level 14 (\$1201- \$1300)	S		\$1,250.50	.	\$250.10				
1515	New Technology - Level 15 (\$1301 - \$1400)	S		\$1,350.50	.	\$270.10				
1516	New Technology - Level 16 (\$1401 - \$1500)	S		\$1,450.50	.	\$290.10				
1517	New Technology - Level 17 (\$1501-\$1600)	S		\$1,550.50	.	\$310.10				
1518	New Technology - Level 18 (\$1601-\$1700)	S		\$1,650.50	.	\$330.10				
1519	New Technology - Level 19 (\$1701-\$1800)	S		\$1,750.50	.	\$350.10				
1520	New Technology - Level 20 (\$1801-\$1900)	S		\$1,850.50	.	\$370.10				
1521	New Technology - Level 21 (\$1901-\$2000)	S		\$1,950.50	.	\$390.10				
1522	New Technology - Level 22 (\$2001-\$2500)	S		\$2,250.50	.	\$450.10				
1523	New Technology - Level 23 (\$2501-\$3000)	S		\$2,750.50	.	\$550.10				
1524	New Technology - Level 24 (\$3001-\$3500)	S		\$3,250.50	.	\$650.10				
1525	New Technology - Level 25 (\$3501-\$4000)	S		\$3,750.50	.	\$750.10				
1526	New Technology - Level 26 (\$4001-\$4500)	S		\$4,250.50	.	\$850.10				
1527	New Technology - Level 27 (\$4501-\$5000)	S		\$4,750.50	.	\$950.10				
1528	New Technology - Level 28 (\$5001-\$5500)	S		\$5,250.50	.	\$1,050.10				
1529	New Technology - Level 29 (\$5501-\$6000)	S		\$5,750.50	.	\$1,150.10				
1530	New Technology - Level 30 (\$6001-\$6500)	S		\$6,250.50	.	\$1,250.10				
1531	New Technology - Level 31 (\$6501-\$7000)	S		\$6,750.50	.	\$1,350.10				
1532	New Technology - Level 32 (\$7001-\$7500)	S		\$7,250.50	.	\$1,450.10				
1533	New Technology - Level 33 (\$7501-\$8000)	S		\$7,750.50	.	\$1,550.10				
1534	New Technology - Level 34 (\$8001-\$8500)	S		\$8,250.50	.	\$1,650.10	\$1,600.00			Copayments capped at inpatient deducti
1535	New Technology - Level 35 (\$8501-\$9000)	S		\$8,750.50	.	\$1,750.10	\$1,600.00			Copayments capped at inpatient deducti
1536	New Technology - Level 36 (\$9001-\$9500)	S		\$9,250.50	.	\$1,850.10	\$1,600.00			Copayments capped at inpatient deducti
1537	New Technology - Level 37 (\$9501-\$10000)	S		\$9,750.50	.	\$1,950.10	\$1,600.00			Copayments capped at inpatient deducti
1539	New Technology - Level 2 (\$51 - \$100)	T		\$75.50	.	\$15.10				
1540	New Technology - Level 3 (\$101 - \$200)	T		\$150.50	.	\$30.10				
1541	New Technology - Level 4 (\$201 - \$300)	T		\$250.50	.	\$50.10				
1542	New Technology - Level 5 (\$301 - \$400)	T		\$350.50	.	\$70.10				
1543	New Technology - Level 6 (\$401 - \$500)	T		\$450.50	.	\$90.10				
1544	New Technology - Level 7 (\$501 - \$600)	T		\$550.50	.	\$110.10				
1545	New Technology - Level 8 (\$601 - \$700)	T		\$650.50	.	\$130.10				
1546	New Technology - Level 9 (\$701 - \$800)	T		\$750.50	.	\$150.10				
1547	New Technology - Level 10 (\$801 - \$900)	T		\$850.50	.	\$170.10				
1548	New Technology - Level 11 (\$901 - \$1000)	T		\$950.50	.	\$190.10				
1549	New Technology - Level 12 (\$1001 - \$1100)	T		\$1,050.50	.	\$210.10				
1550	New Technology - Level 13 (\$1101 - \$1200)	T		\$1,150.50	.	\$230.10				
1551	New Technology - Level 14 (\$1201- \$1300)	T		\$1,250.50	.	\$250.10				
1552	New Technology - Level 15 (\$1301 - \$1400)	T		\$1,350.50	.	\$270.10				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
1553	New Technology - Level 16 (\$1401 - \$1500)	T		\$1,450.50	.	\$290.10				
1554	New Technology - Level 17 (\$1501-\$1600)	T		\$1,550.50	.	\$310.10				
1555	New Technology - Level 18 (\$1601-\$1700)	T		\$1,650.50	.	\$330.10				
1556	New Technology - Level 19 (\$1701-\$1800)	T		\$1,750.50	.	\$350.10				
1557	New Technology - Level 20 (\$1801-\$1900)	T		\$1,850.50	.	\$370.10				
1558	New Technology - Level 21 (\$1901-\$2000)	T		\$1,950.50	.	\$390.10				
1559	New Technology - Level 22 (\$2001-\$2500)	T		\$2,250.50	.	\$450.10				
1560	New Technology - Level 23 (\$2501-\$3000)	T		\$2,750.50	.	\$550.10				
1561	New Technology - Level 24 (\$3001-\$3500)	T		\$3,250.50	.	\$650.10				
1562	New Technology - Level 25 (\$3501-\$4000)	T		\$3,750.50	.	\$750.10				
1563	New Technology - Level 26 (\$4001-\$4500)	T		\$4,250.50	.	\$850.10				
1564	New Technology - Level 27 (\$4501-\$5000)	T		\$4,750.50	.	\$950.10				
1565	New Technology - Level 28 (\$5001-\$5500)	T		\$5,250.50	.	\$1,050.10				
1566	New Technology - Level 29 (\$5501-\$6000)	T		\$5,750.50	.	\$1,150.10				
1567	New Technology - Level 30 (\$6001-\$6500)	T		\$6,250.50	.	\$1,250.10				
1568	New Technology - Level 31 (\$6501-\$7000)	T		\$6,750.50	.	\$1,350.10				
1569	New Technology - Level 32 (\$7001-\$7500)	T		\$7,250.50	.	\$1,450.10				
1570	New Technology - Level 33 (\$7501-\$8000)	T		\$7,750.50	.	\$1,550.10				
1571	New Technology - Level 34 (\$8001-\$8500)	T		\$8,250.50	.	\$1,650.10	\$1,600.00			Copayments capped at inpatient deducti
1572	New Technology - Level 35 (\$8501-\$9000)	T		\$8,750.50	.	\$1,750.10	\$1,600.00			Copayments capped at inpatient deducti
1573	New Technology - Level 36 (\$9001-\$9500)	T		\$9,250.50	.	\$1,850.10	\$1,600.00			Copayments capped at inpatient deducti
1574	New Technology - Level 37 (\$9501-\$10000)	T		\$9,750.50	.	\$1,950.10	\$1,600.00			Copayments capped at inpatient deducti
1575	New Technology - Level 38 (\$10,001-\$15,000)	S		\$12,500.50	.	\$2,500.10	\$1,600.00			Copayments capped at inpatient deducti
1576	New Technology - Level 39 (\$15,001-\$20,000)	S		\$17,500.50	.	\$3,500.10	\$1,600.00			Copayments capped at inpatient deducti
1577	New Technology - Level 40 (\$20,001-\$25,000)	S		\$22,500.50	.	\$4,500.10	\$1,600.00			Copayments capped at inpatient deducti
1578	New Technology - Level 41 (\$25,001-\$30,000)	S		\$27,500.50	.	\$5,500.10	\$1,600.00			Copayments capped at inpatient deducti
1579	New Technology - Level 42 (\$30,001-\$40,000)	S		\$35,000.50	.	\$7,000.10	\$1,600.00			Copayments capped at inpatient deducti
1580	New Technology - Level 43 (\$40,001-\$50,000)	S		\$45,000.50	.	\$9,000.10	\$1,600.00			Copayments capped at inpatient deducti
1581	New Technology - Level 44 (\$50,001-\$60,000)	S		\$55,000.50	.	\$11,000.10	\$1,600.00			Copayments capped at inpatient deducti
1582	New Technology - Level 45 (\$60,001-\$70,000)	S		\$65,000.50	.	\$13,000.10	\$1,600.00			Copayments capped at inpatient deducti
1583	New Technology - Level 46 (\$70,001-\$80,000)	S		\$75,000.50	.	\$15,000.10	\$1,600.00			Copayments capped at inpatient deducti
1584	New Technology - Level 47 (\$80,001-\$90,000)	S		\$85,000.50	.	\$17,000.10	\$1,600.00			Copayments capped at inpatient deducti
1585	New Technology - Level 48 (\$90,001-\$100,000)	S		\$95,000.50	.	\$19,000.10	\$1,600.00			Copayments capped at inpatient deducti
1589	New Technology - Level 38 (\$10,001-\$15,000)	T		\$12,500.50	.	\$2,500.10	\$1,600.00			Copayments capped at inpatient deducti
1590	New Technology - Level 39 (\$15,001-\$20,000)	T		\$17,500.50	.	\$3,500.10	\$1,600.00			Copayments capped at inpatient deducti
1591	New Technology - Level 40 (\$20,001-\$25,000)	T		\$22,500.50	.	\$4,500.10	\$1,600.00			Copayments capped at inpatient deducti
1592	New Technology - Level 41 (\$25,001-\$30,000)	T		\$27,500.50	.	\$5,500.10	\$1,600.00			Copayments capped at inpatient deducti
1593	New Technology - Level 42 (\$30,001-\$40,000)	T		\$35,000.50	.	\$7,000.10	\$1,600.00			Copayments capped at inpatient deducti
1594	New Technology - Level 43 (\$40,001-\$50,000)	T		\$45,000.50	.	\$9,000.10	\$1,600.00			Copayments capped at inpatient deducti
1595	New Technology - Level 44 (\$50,001-\$60,000)	T		\$55,000.50	.	\$11,000.10	\$1,600.00			Copayments capped at inpatient deducti
1596	New Technology - Level 45 (\$60,001-\$70,000)	T		\$65,000.50	.	\$13,000.10	\$1,600.00			Copayments capped at inpatient deducti
1597	New Technology - Level 46 (\$70,001-\$80,000)	T		\$75,000.50	.	\$15,000.10	\$1,600.00			Copayments capped at inpatient deducti

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
1598	New Technology - Level 47 (\$80,001-\$90,000)	T		\$85,000.50	.	\$17,000.10	\$1,600.00			Copayments capped at inpatient deducti
1599	New Technology - Level 48 (\$90,001-\$100,000)	T		\$95,000.50	.	\$19,000.10	\$1,600.00			Copayments capped at inpatient deducti
1608	Etanercept injection	K		\$790.781	.	\$158.16			*	
1609	Rho(D) immune globulin h, sd	K		\$33.710	.	\$6.75			*	
1613	Trastuzumab injection	K		\$81.079	.	\$16.22			*	
1630	Hep b ig, im	K		\$136.744	.	\$27.35			*	
1643	Y90 ibritumomab, rx	K		\$65,476.582	.	\$13,095.32	\$1,600.00		*	Copayments capped at inpatient deducti
1656	Factor viii fc fusion recomb	K		\$2.173	.	\$0.44			*	
1658	Injection, belinostat, 10mg	K		\$47.622	.	\$9.53			*	
1660	Injection, oritavancin	K		\$26.894	.	\$5.38			*	
1662	Inj tedizolid phosphate	K		\$1.709	.	\$0.35			*	
1669	Erythro lactobionate /500 mg	K		\$87.328	.	\$17.47			*	
1670	Tetanus immune globulin inj	K		\$540.989	.	\$108.20			*	
1675	P32 Na phosphate	K		\$36.940	.	\$7.39			*	
1683	Basiliximab	K		\$4,389.082	.	\$877.82			*	
1685	Darbepoetin alfa, non-esrd	K		\$2.936	.	\$0.59			*	
1686	Epoetin alfa, non-esrd	K		\$6.876	.	\$1.38			*	
1687	Digoxin immune fab (ovine)	K		\$4,593.574	.	\$918.72			*	
1688	Ethanolamine oleate	K		\$481.062	.	\$96.22			*	
1689	Fomepizole	K		\$7.266	.	\$1.46			*	
1690	Hemin	K		\$31.081	.	\$6.05	\$6.05		*	Inflation-adjusted coinsurance
1694	Ziconotide injection	K		\$9.078	.	\$1.82			*	
1696	Palifermin injection	K		\$26.509	.	\$5.31			*	
1700	Inj secretin synthetic human	K		\$41.738	.	\$8.35			*	
1701	Treprostinil injection	K		\$55.196	.	\$11.04			*	
1704	Humate-P, inj	K		\$1.347	.	\$0.27			*	
1705	Factor viia recomb novoseven	K		\$2.412	.	\$0.49			*	
1710	Clofarabine injection	K		\$29.424	.	\$5.89			*	
1711	Vantas implant	K		\$5,166.292	.	\$1,033.26			*	
1712	Paclitaxel protein bound	K		\$12.056	.	\$2.42			*	
1745	Radium ra223 dichloride ther	K		\$157.461	.	\$31.50			*	
1747	Monovisc inj per dose	K		\$692.752	.	\$138.56			*	
1748	Inj tbo filgrastim 1 microg	K		\$0.426	.	\$0.09			*	
1761	Rolapitant, oral, 1mg	K		\$1.625	.	\$0.33			*	
1809	Injection, alemtuzumab	K		\$2,283.728	.	\$456.75			*	
1823	Injection, dalbavancin	K		\$14.703	.	\$2.95			*	
1824	Ceftaroline fosamil inj	K		\$3.887	.	\$0.78			*	
1825	Ceftazidime and avibactam	K		\$92.479	.	\$18.50			*	
1826	Hyqvia 100mg immunoglobulin	K		\$16.655	.	\$3.34			*	
1827	Factor viii recomb obizur	K		\$3.217	.	\$0.65			*	
1829	Penicillin g benzathine inj	K		\$20.168	.	\$3.48	\$3.48		*	Inflation-adjusted coinsurance
1832	Dimethyl sulfoxide 50% 50 ml	K		\$682.516	.	\$136.51			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
1836	Penicillin g procaine inj	K		\$43.376	.	\$8.68			*	
1844	Factor viii pegylated recomb	K		\$2.106	.	\$0.43			*	
1846	Factor viii nuwiq recomb 1iu	K		\$1.358	.	\$0.28			*	
1847	Injection, inflectra	K		\$18.427	.	\$3.69			*	8% of reference add-on applied
1848	Artiss fibrin sealant	K		\$180.540	.	\$36.11			*	
1849	Foscarnet sodium injection	K		\$57.182	.	\$11.44			*	
1850	Gamma globulin 1 cc inj	K		\$48.465	.	\$9.70			*	
1851	Gamma globulin > 10 cc inj	K		\$484.648	.	\$96.93			*	
1852	Interferon beta-1a inj	K		\$1,819.710	.	\$363.95			*	
1853	Minocycline hydrochloride	K		\$2.399	.	\$0.46	\$0.46		*	Inflation-adjusted coinsurance
1854	Pentobarbital sodium inj	K		\$30.334	.	\$6.07			*	
1856	Factor viii recomb novoeight	K		\$1.283	.	\$0.26			*	
1857	Inj, factor x, (human), 1iu	K		\$9.091	.	\$1.82			*	
1859	Argatroban nonesrd use 1mg	K		\$1.252	.	\$0.26			*	
1861	Inj., bendeka 1 mg	K		\$16.508	.	\$3.31			*	
1862	Gelsyn-3 injection 0.1 mg	K		\$0.615	.	\$0.13			*	
1901	New Technology - Level 49 (\$100,001-\$115,000)	S	1,256.0671	\$107,500.50	.	\$21,500.10	\$1,600.00			Copayments capped at inpatient deducti
1902	New Technology - Level 49 (\$100,001-\$115,000)	T	1,256.0671	\$107,500.50	.	\$21,500.10	\$1,600.00			Copayments capped at inpatient deducti
1903	New Technology - Level 50 (\$115,001-\$130,000)	S	1,431.3314	\$122,500.50	.	\$24,500.10	\$1,600.00			Copayments capped at inpatient deducti
1904	New Technology - Level 50 (\$115,001-\$130,000)	T	1,431.3314	\$122,500.50	.	\$24,500.10	\$1,600.00			Copayments capped at inpatient deducti
1905	New Technology - Level 51 (\$130,001-\$145,000)	S	1,606.5958	\$137,500.50	.	\$27,500.10	\$1,600.00			Copayments capped at inpatient deducti
1906	New Technology - Level 51 (\$130,001-\$145,000)	T	1,606.5958	\$137,500.50	.	\$27,500.10	\$1,600.00			Copayments capped at inpatient deducti
1907	New Technology - Level 52 (\$145,001-\$160,000)	S	1,781.8601	\$152,500.50	.	\$30,500.10	\$1,600.00			Copayments capped at inpatient deducti
1908	New Technology - Level 52 (\$145,001-\$160,000)	T	1,781.8601	\$152,500.50	.	\$30,500.10	\$1,600.00			Copayments capped at inpatient deducti
2024	Generator, ccm, implant	H						*		
2025	Cath, pressure, valve-occlu	H						*		
2026	Orth/devic/drug bn/bn,tis/bn	H						*		
2027	Probe, robotic, water-jet	H						*		
2028	Iris prosthesis	H						*		
2030	Gen, neuro, carot sinus baro	H			.			*		
2031	Hemostatic agent, GI, topic	H			.			*		
2032	Intravertebral fx aug impl	H			.			*		
2033	Cath, trans intra litho/coro	H			.					
2034	Personalized interbody cage	H			.					
2035	Auto cell process sys	H			.					
2036	Cardiac monitor sys	H			.					
2038	Gen, neuro, clo loop, rechg	H			.					
2039	Gen, neuro, imp led, ex cntr	H			.					
2040	Endo, single, urinary tract	H			.					
2616	Brachytx, non-str, Yttrium-90	U	205.7575	\$17,609.76	.	\$3,521.96	\$1,600.00			Copayments capped at inpatient deducti
2632	Iodine I-125 sodium iodide	U	0.5039	\$43.13	.	\$8.63				
2634	Brachytx, non-str, HA, I-125	U	2.1265	\$182.00	.	\$36.40				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
2635	Brachytx, non-str, HA, P-103	U	0.5919	\$50.66	.	\$10.14				
2636	Brachy linear, non-str,P-103	U	0.6065	\$51.91	.	\$10.39				
2638	Brachytx, stranded, I-125	U	0.4457	\$38.15	.	\$7.63				
2639	Brachytx, non-stranded,I-125	U	0.4126	\$35.31	.	\$7.07				
2640	Brachytx, stranded, P-103	U	1.0356	\$88.63	.	\$17.73				
2641	Brachytx, non-stranded,P-103	U	0.9463	\$80.99	.	\$16.20				
2642	Brachytx, stranded, C-131	U	1.0601	\$90.73	.	\$18.15				
2643	Brachytx, non-stranded,C-131	U	0.9525	\$81.52	.	\$16.31				
2645	Brachytx, non-str, Gold-198	U	2.6962	\$230.75	.	\$46.15				
2646	Brachytx, non-str, HDR Ir-192	U	3.9225	\$335.71	.	\$67.15				
2647	Brachytx, NS, Non-HDRIr-192	U	4.0409	\$345.84	.	\$69.17				
2648	Brachytx planar, p-103	U	0.0548	\$4.69	.	\$0.94				
2698	Brachytx, stranded, NOS	U	0.4457	\$38.15	.	\$7.63				
2699	Brachytx, non-stranded, NOS	U	0.4126	\$35.31	.	\$7.07				
2731	Immune globulin, powder	K		\$77.766	.	\$15.08	\$15.08		*	Inflation-adjusted coinsurance
2770	Quinupristin/dalfopristin	K		\$493.970	.	\$98.80			*	
4001	Echo guidance radiotherapy	S	1.6716	\$143.06	.	\$28.62				
4002	Stereoscopic x-ray guidance	S	0.6085	\$52.08	.	\$10.42				
4003	Radiation treatment delivery, MeV <= 5; simple	S	1.7167	\$146.92	.	\$29.39				
4004	Radiation treatment delivery, 6-10 MeV; simple	S	1.4499	\$124.09	.	\$24.82				
4005	Radiation treatment delivery, 11-19 MeV; simple	S	1.4537	\$124.41	.	\$24.89				
4006	Radiation treatment delivery, MeV>=20; simple	S	1.4462	\$123.77	.	\$24.76				
4007	Radiation treatment delivery, MeV<=5; intermediate	S	2.6746	\$228.91	.	\$45.79				
4008	Radiation treatment delivery, 6-10 MeV; intermediate	S	2.0021	\$171.35	.	\$34.27				
4009	Radiation treatment delivery, 11-19 MeV; intermediate	S	1.9946	\$170.71	.	\$34.15				
4010	Radiation treatment delivery, MeV >=20; intermediate	S	1.9834	\$169.75	.	\$33.95				
4011	Radiation treatment delivery, MeV<=5; complex	S	2.6708	\$228.58	.	\$45.72				
4012	Radiation treatment delivery, 6-10 MeV; complex	S	2.6408	\$226.01	.	\$45.21				
4013	Radiation treatment delivery, 11-19 MeV; complex	S	2.6483	\$226.65	.	\$45.33				
4014	Radiation treatment delivery, MeV >=20; complex	S	2.6333	\$225.37	.	\$45.08				
4015	Radiation tx delivery imrt	S	4.0457	\$346.25	.	\$69.25				
4016	Delivery comp imrt	S	4.0344	\$345.28	.	\$69.06				
5012	Clinic Visits and Related Services	V	1.4122	\$120.86	.	\$24.18				
5021	Level 1 Type A ED Visits	V	0.8774	\$75.09	.	\$15.02				
5022	Level 2 Type A ED Visits	V	1.6322	\$139.69	.	\$27.94				
5023	Level 3 Type A ED Visits	V	2.8630	\$245.03	.	\$49.01				
5024	Level 4 Type A ED Visits	V	4.4589	\$381.61	.	\$76.33				
5025	Level 5 Type A ED Visits	V	6.4043	\$548.11	.	\$109.63				
5031	Level 1 Type B ED Visits	V	0.7147	\$61.17	.	\$12.24				
5032	Level 2 Type B ED Visits	V	1.3020	\$111.43	.	\$22.29				
5033	Level 3 Type B ED Visits	V	2.2751	\$194.71	.	\$38.95				
5034	Level 4 Type B ED Visits	V	3.2683	\$279.72	.	\$55.95				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
5035	Level 5 Type B ED Visits	V	4.0327	\$345.14	.	\$69.03				
5041	Critical Care	S	8.9703	\$767.72	.	\$153.55				
5045	Trauma Response with Critical Care	S	13.4549	\$1,151.54	.	\$230.31				
5051	Level 1 Skin Procedures	T	2.1100	\$180.58	.	\$36.12				
5052	Level 2 Skin Procedures	T	4.3590	\$373.07	.	\$74.62				
5053	Level 3 Skin Procedures	T	6.7880	\$580.95	.	\$116.19				
5054	Level 4 Skin Procedures	T	20.1655	\$1,725.86	.	\$345.18				
5055	Level 5 Skin Procedures	T	38.0095	\$3,253.04	.	\$650.61				
5061	Hyperbaric Oxygen	S	1.4613	\$125.07	.	\$25.02				
5071	Level 1 Excision/ Biopsy/ Incision and Drainage	T	7.5828	\$648.97	.	\$129.80				
5072	Level 2 Excision/ Biopsy/ Incision and Drainage	J1	17.5212	\$1,499.55	.	\$299.91				
5073	Level 3 Excision/ Biopsy/ Incision and Drainage	J1	30.1835	\$2,583.25	.	\$516.65				
5091	Level 1 Breast/Lymphatic Surgery and Related Procedures	J1	40.1682	\$3,437.80	.	\$687.56				
5092	Level 2 Breast/Lymphatic Surgery and Related Procedures	J1	69.4415	\$5,943.15	.	\$1,188.63				
5093	Level 3 Breast/Lymphatic Surgery and Related Procedures	J1	102.8888	\$8,805.74	.	\$1,761.15	\$1,600.00			Copayments capped at inpatient deductible
5094	Procedures	J1	194.9380	\$16,683.77	.	\$3,336.76	\$1,600.00			Copayments capped at inpatient deductible
5101	Level 1 Strapping and Cast Application	T	1.7031	\$145.76	.	\$29.16				
5102	Level 2 Strapping and Cast Application	T	2.8032	\$239.91	.	\$47.99				
5111	Level 1 Musculoskeletal Procedures	T	2.4188	\$207.01	.	\$41.41				
5112	Level 2 Musculoskeletal Procedures	J1	16.7613	\$1,434.52	.	\$286.91				
5113	Level 3 Musculoskeletal Procedures	J1	34.7802	\$2,976.66	.	\$595.34				
5114	Level 4 Musculoskeletal Procedures	J1	77.2872	\$6,614.63	.	\$1,322.93				
5115	Level 5 Musculoskeletal Procedures	J1	152.4576	\$13,048.08	.	\$2,609.62	\$1,600.00			Copayments capped at inpatient deductible
5116	Level 6 Musculoskeletal Procedures	J1	255.8583	\$21,897.63	.	\$4,379.53	\$1,600.00			Copayments capped at inpatient deductible
5151	Level 1 Airway Endoscopy	T	2.0886	\$178.75	.	\$35.75				
5152	Level 2 Airway Endoscopy	T	4.4066	\$377.14	.	\$75.43				
5153	Level 3 Airway Endoscopy	J1	18.6780	\$1,598.56	.	\$319.72				
5154	Level 4 Airway Endoscopy	J1	38.9513	\$3,333.65	.	\$666.73				
5155	Level 5 Airway Endoscopy	J1	72.2916	\$6,187.08	.	\$1,237.42				
5161	Level 1 ENT Procedures	T	2.4283	\$207.83	.	\$41.57				
5162	Level 2 ENT Procedures	T	5.3376	\$456.82	.	\$91.37				
5163	Level 3 ENT Procedures	J1	16.2194	\$1,388.14	.	\$277.63				
5164	Level 4 ENT Procedures	J1	33.2421	\$2,845.03	.	\$569.01				
5165	Level 5 ENT Procedures	J1	62.3903	\$5,339.67	.	\$1,067.94				
5166	Cochlear Implant Procedure	J1	389.5196	\$33,337.03	\$7,276.58	\$6,667.41	\$1,600.00			Copayments capped at inpatient deductible
5181	Level 1 Vascular Procedures	T	6.7594	\$578.50	.	\$115.70				
5182	Level 2 Vascular Procedures	J1	17.3845	\$1,487.85	.	\$297.57				
5183	Level 3 Vascular Procedures	J1	34.8072	\$2,978.97	.	\$595.80				
5184	Level 4 Vascular Procedures	J1	60.0544	\$5,139.76	.	\$1,027.96				
5191	Level 1 Endovascular Procedures	J1	34.5675	\$2,958.46	\$863.75	\$591.70				
5192	Level 2 Endovascular Procedures	J1	60.9383	\$5,215.40	.	\$1,043.08				
5193	Level 3 Endovascular Procedures	J1	124.0324	\$10,615.31	.	\$2,123.07	\$1,600.00			Copayments capped at inpatient deductible

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
5194	Level 4 Endovascular Procedures	J1	200.7081	\$17,177.60	.	\$3,435.52	\$1,600.00			Copayments capped at inpatient deducti
5200	Implantation Wireless PA Pressure Monitor	J1	319.0415	\$27,305.17	.	\$5,461.04	\$1,600.00			Copayments capped at inpatient deducti
5211	Level 1 Electrophysiologic Procedures	J1	13.0521	\$1,117.06	.	\$223.42				
5212	Level 2 Electrophysiologic Procedures	J1	78.6674	\$6,732.75	.	\$1,346.55				
5213	Level 3 Electrophysiologic Procedures	J1	274.3622	\$23,481.29	.	\$4,696.26	\$1,600.00			Copayments capped at inpatient deducti
5221	Level1 Pacemaker and Similar Procedures	T	39.1532	\$3,350.93	.	\$670.19				
5222	Level 2 Pacemaker and Similar Procedures	J1	95.3762	\$8,162.77	.	\$1,632.56	\$1,600.00			Copayments capped at inpatient deducti
5223	Level 3 Pacemaker and Similar Procedures	J1	120.6844	\$10,328.77	.	\$2,065.76	\$1,600.00			Copayments capped at inpatient deducti
5224	Level 4 Pacemaker and Similar Procedures	J1	218.1692	\$18,672.01	.	\$3,734.41	\$1,600.00			Copayments capped at inpatient deducti
5231	Level 1 ICD and Similar Procedures	J1	266.6159	\$22,818.32	.	\$4,563.67	\$1,600.00			Copayments capped at inpatient deducti
5232	Level 2 ICD and Similar Procedures	J1	374.7891	\$32,076.33	.	\$6,415.27	\$1,600.00			Copayments capped at inpatient deducti
5241	Level 1 Blood Product Exchange and Related Services	S	4.7643	\$407.75	.	\$81.55				
5242	Level 2 Blood Product Exchange and Related Services	S	15.8888	\$1,359.84	.	\$271.97				
5243	Services	S	48.6067	\$4,160.00	.	\$832.00				
5244	Services	J1	493.4673	\$42,233.40	.	\$8,446.68	\$1,600.00			Copayments capped at inpatient deducti
5301	Level 1 Upper GI Procedures	T	9.6455	\$825.51	.	\$165.11				
5302	Level 2 Upper GI Procedures	J1	20.3492	\$1,741.59	.	\$348.32				
5303	Level 3 Upper GI Procedures	J1	38.0989	\$3,260.69	.	\$652.14				
5311	Level 1 Lower GI Procedures	T	9.7101	\$831.04	.	\$166.21				
5312	Level 2 Lower GI Procedures	T	12.6530	\$1,082.91	.	\$216.59				
5313	Level 3 Lower GI Procedures	J1	30.0224	\$2,569.47	.	\$513.90				
5331	Complex GI Procedures	J1	61.2341	\$5,240.72	.	\$1,048.15				
5341	Abdominal/Peritoneal/Biliary and Related Procedures	J1	41.3849	\$3,541.93	.	\$708.39				
5361	Level 1 Laparoscopy and Related Services	J1	60.9003	\$5,212.15	.	\$1,042.43				
5362	Level 2 Laparoscopy and Related Services	J1	106.1787	\$9,087.30	.	\$1,817.46	\$1,600.00			Copayments capped at inpatient deducti
5371	Level 1 Urology and Related Services	T	2.5106	\$214.87	.	\$42.98				
5372	Level 2 Urology and Related Services	J1	7.3066	\$625.34	.	\$125.07				
5373	Level 3 Urology and Related Services	J1	21.6729	\$1,854.88	.	\$370.98				
5374	Level 4 Urology and Related Services	J1	37.4496	\$3,205.12	.	\$641.03				
5375	Level 5 Urology and Related Services	J1	54.9416	\$4,702.18	.	\$940.44				
5376	Level 6 Urology and Related Services	J1	99.9887	\$8,557.53	.	\$1,711.51	\$1,600.00			Copayments capped at inpatient deducti
5377	Level 7 Urology and Related Services	J1	140.5395	\$12,028.07	.	\$2,405.62	\$1,600.00			Copayments capped at inpatient deducti
5378	Level 8 Urology and Related Services	J1	225.2931	\$19,281.71	.	\$3,856.35	\$1,600.00			Copayments capped at inpatient deducti
5401	Dialysis	S	7.3672	\$630.52	.	\$126.11				
5411	Level 1 Gynecologic Procedures	T	2.0813	\$178.13	.	\$35.63				
5412	Level 2 Gynecologic Procedures	T	3.4113	\$291.96	.	\$58.40				
5413	Level 3 Gynecologic Procedures	T	8.2196	\$703.47	.	\$140.70				
5414	Level 4 Gynecologic Procedures	J1	33.0366	\$2,827.44	.	\$565.49				
5415	Level 5 Gynecologic Procedures	J1	54.1580	\$4,635.11	.	\$927.03				
5416	Level 6 Gynecologic Procedures	J1	80.9202	\$6,925.56	\$1,404.15	\$1,385.12				
5431	Level 1 Nerve Procedures	J1	21.0028	\$1,797.52	.	\$359.51				
5432	Level 2 Nerve Procedures	J1	72.1931	\$6,178.65	.	\$1,235.73				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
5441	Level 1 Nerve Injections	T	3.1769	\$271.89	.	\$54.38				
5442	Level 2 Nerve Injections	T	7.5286	\$644.34	.	\$128.87				
5443	Level 3 Nerve Injections	T	9.9571	\$852.18	.	\$170.44				
5461	Level 1 Neurostimulator and Related Procedures	J1	37.9468	\$3,247.68	.	\$649.54				
5462	Level 2 Neurostimulator and Related Procedures	J1	77.1613	\$6,603.85	.	\$1,320.77				
5463	Level 3 Neurostimulator and Related Procedures	J1	139.6575	\$11,952.59	.	\$2,390.52	\$1,600.00			Copayments capped at inpatient deducti
5464	Level 4 Neurostimulator and Related Procedures	J1	251.3917	\$21,515.36	.	\$4,303.08	\$1,600.00			Copayments capped at inpatient deducti
5465	Level 5 Neurostimulator and Related Procedures	J1	343.0330	\$29,358.48	.	\$5,871.70	\$1,600.00			Copayments capped at inpatient deducti
5471	Implantation of Drug Infusion Device	J1	197.9139	\$16,938.46	.	\$3,387.70	\$1,600.00			Copayments capped at inpatient deducti
5481	Laser Eye Procedures	T	6.2017	\$530.77	.	\$106.16				
5491	Level 1 Intraocular Procedures	J1	25.2315	\$2,159.44	.	\$431.89				
5492	Level 2 Intraocular Procedures	J1	46.6855	\$3,995.58	.	\$799.12				
5493	Level 3 Intraocular Procedures	J1	84.3318	\$7,217.54	.	\$1,443.51				
5494	Level 4 Intraocular Procedures	J1	187.1847	\$16,020.20	.	\$3,204.04	\$1,600.00			Copayments capped at inpatient deducti
5495	Level 5 Intraocular Procedures	J1	211.3686	\$18,089.98	.	\$3,618.00	\$1,600.00			Copayments capped at inpatient deducti
5501	Level 1 Extraocular, Repair, and Plastic Eye Procedure	T	3.0930	\$264.71	.	\$52.95				
5502	Level 2 Extraocular, Repair, and Plastic Eye Procedure	T	10.1962	\$872.64	.	\$174.53				
5503	Level 3 Extraocular, Repair, and Plastic Eye Procedure	J1	24.7032	\$2,114.22	.	\$422.85				
5504	Level 4 Extraocular, Repair, and Plastic Eye Procedure	J1	40.8424	\$3,495.50	.	\$699.10				
5521	Level 1 Imaging without Contrast	S	1.0151	\$86.88	.	\$17.38				
5522	Level 2 Imaging without Contrast	S	1.2488	\$106.88	.	\$21.38				
5523	Level 3 Imaging without Contrast	S	2.7285	\$233.52	.	\$46.71				
5524	Level 4 Imaging without Contrast	S	5.8787	\$503.13	.	\$100.63				
5571	Level 1 Imaging with Contrast	S	2.1071	\$180.34	.	\$36.07				
5572	Level 2 Imaging with Contrast	S	4.3048	\$368.43	.	\$73.69				
5573	Level 3 Imaging with Contrast	S	8.6551	\$740.75	.	\$148.15				
5591	Level 1 Nuclear Medicine and Related Services	S	4.5415	\$388.68	.	\$77.74				
5592	Level 2 Nuclear Medicine and Related Services	S	5.8947	\$504.50	.	\$100.90				
5593	Level 3 Nuclear Medicine and Related Services	S	15.5082	\$1,327.27	.	\$265.46				
5594	Level 4 Nuclear Medicine and Related Services	S	17.4020	\$1,489.35	.	\$297.87				
5611	Level 1 Therapeutic Radiation Treatment Preparation	S	1.5584	\$133.38	\$32.03	\$26.68				
5612	Level 2 Therapeutic Radiation Treatment Preparation	S	4.1914	\$358.72	.	\$71.75				
5613	Level 3 Therapeutic Radiation Treatment Preparation	S	15.6648	\$1,340.67	.	\$268.14				
5621	Level 1 Radiation Therapy	S	1.4300	\$122.39	.	\$24.48				
5622	Level 2 Radiation Therapy	S	3.0722	\$262.93	.	\$52.59				
5623	Level 3 Radiation Therapy	S	6.6889	\$572.47	.	\$114.50				
5624	Level 4 Radiation Therapy	S	8.4328	\$721.72	.	\$144.35				
5625	Level 5 Radiation Therapy	S	15.4609	\$1,323.22	.	\$264.65				
5626	Level 6 Radiation Therapy	S	20.6514	\$1,767.45	.	\$353.49				
5627	Level 7 Radiation Therapy	J1	89.8589	\$7,690.57	.	\$1,538.12				
5661	Therapeutic Nuclear Medicine	S	2.9179	\$249.73	.	\$49.95				
5671	Level 1 Pathology	S	0.5858	\$50.14	.	\$10.03				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
5672	Level 2 Pathology	S	1.8374	\$157.25	.	\$31.45				
5673	Level 3 Pathology	S	3.7870	\$324.11	.	\$64.83				
5674	Level 4 Pathology	S	9.0730	\$776.51	.	\$155.31				
5691	Level 1 Drug Administration	S	0.4951	\$42.37	.	\$8.48				
5692	Level 2 Drug Administration	S	0.7883	\$67.47	.	\$13.50				
5693	Level 3 Drug Administration	S	2.4136	\$206.57	.	\$41.32				
5694	Level 4 Drug Administration	S	3.8864	\$332.62	.	\$66.53				
5721	Level 1 Diagnostic Tests and Related Services	S	1.6992	\$145.43	.	\$29.09				
5722	Level 2 Diagnostic Tests and Related Services	S	3.2723	\$280.06	.	\$56.02				
5723	Level 3 Diagnostic Tests and Related Services	S	5.6485	\$483.43	.	\$96.69				
5724	Level 4 Diagnostic Tests and Related Services	S	10.9176	\$934.38	.	\$186.88				
5731	Level 1 Minor Procedures	S	0.2916	\$24.96	.	\$5.00				
5732	Level 2 Minor Procedures	S	0.3968	\$33.96	.	\$6.80				
5733	Level 3 Minor Procedures	S	0.6716	\$57.48	.	\$11.50				
5734	Level 4 Minor Procedures	S	1.3567	\$116.11	.	\$23.23				
5735	Level 5 Minor Procedures	S	4.4116	\$377.57	.	\$75.52				
5741	Level 1 Electronic Analysis of Devices	S	0.4090	\$35.00	.	\$7.00				
5742	Level 2 Electronic Analysis of Devices	S	1.1662	\$99.81	.	\$19.97				
5743	Level 3 Electronic Analysis of Devices	S	3.2325	\$276.65	.	\$55.33				
5771	Cardiac Rehabilitation	S	1.4029	\$120.07	.	\$24.02				
5781	Resuscitation and Cardioversion	S	6.8720	\$588.14	.	\$117.63				
5791	Pulmonary Treatment	S	2.2375	\$191.50	.	\$38.30				
5801	Ventilation Initiation and Management	S	6.5049	\$556.72	.	\$111.35				
5811	Manipulation Therapy	S	0.2919	\$24.98	.	\$5.00				
5821	Level 1 Health and Behavior Services	S	0.3468	\$29.68	.	\$5.94				
5822	Level 2 Health and Behavior Services	S	0.8863	\$75.85	.	\$15.17				
5823	Level 3 Health and Behavior Services	S	1.7024	\$145.70	.	\$29.14				
5853	Partial Hospitalization (3 or more services) for CMHCs	P	1.6673	\$142.70	.	\$28.54				
5863	Partial Hospitalization (3 or more services) for Hospital	P	3.1340	\$268.22	.	\$53.65				
5871	Dental Procedures	S	20.1254	\$1,722.43	.	\$344.49				
5881	Ancillary Outpatient Services When Patient Dies	J1	143.0383	\$12,241.93	.	\$2,448.39	\$1,600.00			Copayments capped at inpatient deducti
7043	Infliximab not biosimilar 10mg	K		\$32.907	.	\$6.59			*	
7046	Doxorubicin inj 10mg	K		\$87.978	.	\$17.60			*	
7048	Alteplase recombinant	K		\$89.146	.	\$17.83			*	
7308	Aminolevulinic acid hcl top	K		\$391.230	.	\$78.25			*	
8004	Ultrasound Composite	S	3.5363	\$302.65	.	\$60.53				
8005	CT and CTA without Contrast Composite	S	2.6602	\$227.67	.	\$45.54				
8006	CT and CTA with Contrast Composite	S	5.0729	\$434.16	.	\$86.84				
8007	MRI and MRA without Contrast Composite	S	6.1596	\$527.17	.	\$105.44				
8008	MRI and MRA with Contrast Composite	S	9.8816	\$845.72	.	\$169.15				
8010	Mental Health Services Composite	S	3.1340	\$268.22	.	\$53.65				
8011	Comprehensive Observation Services	J2	28.4982	\$2,439.02	.	\$487.81				

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9002	Tenecteplase injection	K		\$152.696	.	\$30.54			*	
9003	Palivizumab	K		\$339.680	.	\$67.94			*	
9004	Injection, inclisiran, 1 mg	G		\$12.059	.	\$2.42			*	
9005	Reteplase injection	K		\$2,791.652	.	\$558.34			*	
9006	Tacrolimus injection	K		\$246.085	.	\$49.22			*	
9007	Inj cutaquig 100 mg	K		\$14.386	.	\$2.88			*	
9008	Inj tezepelumab-ekko, 1mg	G		\$18.729	.	\$3.73	\$3.73		*	Inflation-adjusted coinsurance
9009	Inj, vutrisiran, 1 mg	G		\$4,940.950	.	\$988.19			*	
9010	Inj efgartigimod 2mg	G		\$31.811	.	\$6.37			*	
9011	MmrV vaccine sc	K		\$160.000	.	\$32.00			*	
9012	Arsenic trioxide injection	K		\$12.966	.	\$2.60			*	
9013	Inj risankizumab-rzaa 1 mg	G		\$15.519	.	\$3.11			*	
9016	Inj., triptorelin xr 3.75 mg	K		\$3,141.978	.	\$628.40			*	
9017	Inj. byooviz, 0.1 mg	G		\$220.828	.	\$44.17			*	8% of reference add-on applied
9018	Inj, rimabotulinumtoxinB	K		\$12.721	.	\$2.55			*	
9020	Argatroban nonesrd (accord)	K		\$0.460	.	\$0.10			*	
9021	Argatroban dialysis (accord)	K		\$0.460	.	\$0.10			*	
9022	Argatroban nonesrd (auromed)	K		\$1.642	.	\$0.33			*	
9023	Argatroban dialysis, auromed	K		\$1.642	.	\$0.33			*	
9024	Amphotericin b lipid complex	K		\$11.130	.	\$2.16	\$2.16		*	Inflation-adjusted coinsurance
9025	Inj glucagon hcl, fresenius	K		\$101.412	.	\$20.29			*	
9026	Inj, bortezomib, dr. reddy's	K		\$48.547	.	\$9.71			*	
9027	Inj, bortezomib freseniuskab	K		\$48.547	.	\$9.71			*	
9028	Inj inotuzumab ozogam 0.1 mg	K		\$2,529.553	.	\$505.92			*	
9029	Inj., guselkumab, 1 mg	K		\$75.789	.	\$15.16			*	
9030	Inj., copanlisib, 1 mg	K		\$85.676	.	\$17.14			*	
9032	Baclofen 10 MG injection	K		\$182.487	.	\$36.50			*	
9033	Cidofovir injection	K		\$577.031	.	\$115.41			*	
9034	Inj cuvitru, 100 mg	K		\$16.275	.	\$3.26	\$3.26		*	Inflation-adjusted coinsurance
9035	Axicabtagene ciloleucel car+	K		\$449,440.000	.	\$89,888.00	\$1,600.00		*	Copayments capped at inpatient deducti
9036	Injection, renflexis	K		\$35.547	.	\$7.11			*	
9037	Aripiprazole injection	K		\$5.250	.	\$1.05			*	
9038	Inj estrogen conjugate	K		\$371.893	.	\$74.38			*	
9039	Dimecaprol injection	K		\$59.809	.	\$11.97			*	
9040	Corticotropin injection	K		\$3,819.780	.	\$763.96			*	
9041	Epoetin beta esrd use	K		\$1.647	.	\$0.33			*	
9042	Glucagon hydrochloride	K		\$195.175	.	\$39.04			*	
9043	Inj, afstyla, 1 i.u.	K		\$1.436	.	\$0.29			*	
9044	Ibutilide fumarate injection	K		\$271.858	.	\$54.38			*	
9045	Idursulfase injection	K		\$542.918	.	\$108.59			*	
9046	Inj., fibryga, 1 mg	K		\$1.098	.	\$0.22			*	
9047	Leuprolide acetate injeciton	K		\$10.057	.	\$2.02			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9048	Inj, alymsys, 10 mg	G		\$72.518	.	\$14.51			*	8% of reference add-on applied
9049	Inj, oliceridine 0.1 mg	G		\$1.100	.	\$0.00			*	
9050	Leuprolide inj, camcevi, 1mg	G		\$78.308	.	\$15.67			*	
9051	Inj, lanreotide, (cipla) 1mg	G		\$51.378	.	\$10.28			*	
9053	Fluorodopa f-18 diag per mci	G		\$415.520	.	\$0.00				
9054	Lutetium lu 177 vipivotide	G		\$229.696	.	\$45.94			*	
9055	Gallium locametz 1 millicuri	G		\$871.504	.	\$0.00			*	
9057	Inj nivolumab 3mg/1mg	G		\$183.630	.	\$36.73			*	
9058	Buprenorphine implant 74.2mg	K		\$1,311.750	.	\$262.35				
9059	Vonvendi inj 1 iu vwf:cco	K		\$1.781	.	\$0.36			*	
9065	Argatroban esrd dialysis 1mg	K		\$1.252	.	\$0.26			*	
9067	Lutetium lu 177 dotatate ther	K		\$289.976	.	\$58.00			*	
9068	Smallpox&monkeypox vac 0.5ml	K		\$0.010	.	\$0.00				
9069	Phenobarbital sodium inj	K		\$39.383	.	\$7.88			*	
9070	Inj luxturna 1 billion vec g	K		\$2,926.885	.	\$585.38			*	
9071	Capsaicin 8% patch	K		\$3.274	.	\$0.66			*	
9073	Buprenorph xr 100 mg or less	K		\$1,886.367	.	\$377.28			*	
9074	Makena, 10 mg	K		\$14.735	.	\$2.95			*	
9075	Inj, kovaltry, 1 i.u.	K		\$1.436	.	\$0.29			*	
9078	Testosterone undecanoate 1mg	K		\$1.904	.	\$0.36	\$0.36		*	Inflation-adjusted coinsurance
9079	Genvisc 850, inj, 1mg	K		\$6.105	.	\$1.23			*	
9080	Fludarabine phosphate inj	K		\$604.748	.	\$120.95			*	
9087	Inj, clevidipine butyrate	K		\$3.062	.	\$0.62			*	
9088	Peng benzathine/procaine inj	K		\$15.673	.	\$2.76	\$2.76		*	Inflation-adjusted coinsurance
9094	Radiesse injection	K		\$167.360	.	\$33.48			*	
9095	Inj, sculptra, 0.5mg	K		\$1.020	.	\$0.21			*	
9097	Inj retacrit non-esrd use	K		\$7.495	.	\$1.50			*	
9099	Inj fosnetupitant, palonoset	K		\$371.999	.	\$74.40			*	
9100	Inj, bortezomib, hospira	K		\$3.892	.	\$0.78			*	
9101	Vaccinia vrs vac 0.3 ml perq	K		\$0.010	.	\$0.00				
9102	Inj, fulvestrant (teva)	K		\$21.200	.	\$4.24			*	
9103	Inj, fulvestrant (fresenius)	K		\$1.653	.	\$0.34			*	
9104	Antithymocyte globulin rabbit	K		\$920.534	.	\$184.11			*	
9105	Inj pemetrexed (teva) 10mg	K		\$12.300	.	\$2.47			*	
9106	Inj, bupivacaine (posimir)	G		\$0.502	.	\$0.00			*	
9107	Inj, aponvie, 1 mg	G		\$1.867	.	\$0.00				
9108	Thyrotropin injection	K		\$2,001.485	.	\$400.30			*	
9109	Inj, elahere, 1 mg	G		\$65.802	.	\$13.17			*	
9110	Inj, tremelimumab-actl, 1 mg	G		\$136.560	.	\$27.32			*	
9111	Inj teclistamab cqv 0.5 mg	G		\$30.935	.	\$6.19			*	
9112	Inj teplizumab mzwv 5 mcg	G		\$36.273	.	\$7.26			*	
9113	Inj olipudase alfa-rpcp 1mg	G		\$377.508	.	\$75.51			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9114	Inj eflapegrastim-xnst 0.1mg	G		\$31.771	.	\$6.36			*	
9115	Inj, spesolimab-sbzo, 1 mg	G		\$60.223	.	\$12.05			*	
9116	Chloroprocaine opht gel, 1mg	G		\$0.721	.	\$0.00			*	
9117	Inj, cimerli, 0.1 mg	G		\$279.498	.	\$55.90			*	
9118	Inj, fylnetra, 0.5 mg	G		\$220.833	.	\$44.17			*	
9119	Inj sodium thiosulfate 100mg	G		\$96.284	.	\$19.26			*	
9120	Injection, Fulvestrant	K		\$9.470	.	\$1.90			*	
9122	Triptorelin pamoate	K		\$382.392	.	\$76.48			*	
9123	Inj pemetrexed, hospira 10mg	K		\$9.997	.	\$2.00			*	
9125	Risperidone, long acting	K		\$12.023	.	\$2.41			*	
9126	Natalizumab injection	K		\$24.863	.	\$4.98			*	
9127	Inj pemetrexed (accord) 10mg	K		\$9.656	.	\$1.94			*	
9128	Inj pemetrexed (sandoz) 10mg	K		\$1.731	.	\$0.35			*	
9129	Inj, stimufend, 0.5 mg	K		\$358.354	.	\$71.68			*	
9130	Inj, Imm Glob Bivigam, 500mg	K		\$72.963	.	\$14.60			*	
9131	Inj, Ado-trastuzumab Emt 1mg	K		\$38.325	.	\$7.67			*	
9132	Prothrombin complex kcentra	K		\$2.183	.	\$0.44			*	
9133	Rabies ig, im/sc	K		\$284.678	.	\$56.94			*	
9134	Rabies ig, heat treated	K		\$250.093	.	\$50.02			*	
9135	Varicella-zoster ig, im	K		\$2,257.316	.	\$441.53	\$441.53		*	Inflation-adjusted coinsurance
9136	Leuprolide depot cipla 7.5mg	G		\$425.478	.	\$85.10			*	
9138	Inj, hemgenix, per tx dose	G		\$0.000	.	\$0.00			*	
9139	Rabies vaccine, im	K		\$329.989	.	\$66.00			*	
9140	Rabies vaccine, id	K		\$255.140	.	\$51.03			*	
9141	Inj onase abepar-xioi treat	K		\$0.000	.	\$0.00			*	
9142	Fecal microbiota jsln 1 ml	G		\$61.800	.	\$12.36			*	
9144	Inj, panzyga, 500 mg	K		\$65.741	.	\$13.15			*	
9145	Inj, invega hafyera/trinza	K		\$12.108	.	\$2.43			*	
9146	Inj, ixinity, 1 i.u.	K		\$1.746	.	\$0.35			*	
9149	Inj ublituximab-xiyy, 1 mg	G		\$67.522	.	\$13.51			*	
9150	Inj mosunetuzumab-axgb, 1 mg	G		\$611.881	.	\$122.38			*	
9151	Inj apotex/bendamustine 1 mg	K		\$33.058	.	\$6.62			*	
9152	Paclitaxel (american regent)	K		\$16.226	.	\$3.25			*	
9153	Inj bendamustine, baxter 1mg	K		\$23.958	.	\$4.80			*	
9154	Inj, bendamustine, 1 mg	G		\$33.325	.	\$6.67			*	
9155	Inj, lenacapavir, 1 mg	G		\$21.667	.	\$4.34			*	
9156	Inj pemetrexed ditromethamin	K		\$7.508	.	\$1.51			*	
9157	Inj, lecanemab-irmb, 1mg	K		\$1.312	.	\$0.26			*	
9158	Inj, pegcetacoplan 1 mg	G		\$150.380	.	\$30.08			*	
9159	Inj, vegzelma, 10 mg	G		\$69.772	.	\$13.96			*	
9171	Factor ix idelvion inj	K		\$4.932	.	\$0.99			*	
9173	Injection, fulphila	K		\$111.145	.	\$22.23			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9174	Inj, durolane 1 mg	K		\$6.061	.	\$1.22			*	
9178	Inj., meropenem, vaborbactam	K		\$2.020	.	\$0.41	\$0.41		*	Inflation-adjusted coinsurance
9179	Inj., aristada initio, 1 mg	K		\$3.060	.	\$0.62			*	
9180	Inj., patisiran, 0.1 mg	K		\$100.472	.	\$20.10			*	
9181	Inj., perseris, 0.5 mg	K		\$11.669	.	\$2.34			*	
9182	Inj mogamulizumab-kpkc, 1 mg	K		\$226.706	.	\$45.35			*	
9183	Inj., plazomicin, 5 mg	K		\$3.356	.	\$0.68			*	
9186	Inj., rituximab, 10 mg	K		\$81.037	.	\$16.21			*	
9187	Injection, burosumab-twza 1m	K		\$426.072	.	\$84.42	\$84.42		*	Inflation-adjusted coinsurance
9188	Inj crotalidae im f(ab')2 eq	K		\$1,019.456	.	\$203.90			*	
9189	Inj., ibalizumab-uiyk, 10 mg	K		\$74.292	.	\$14.73	\$14.73		*	Inflation-adjusted coinsurance
9193	Nivestym	K		\$0.326	.	\$0.07			*	8% of reference add-on applied
9194	Tisagenlecleucel car-pos t	K		\$466,069.908	.	\$93,213.99	\$1,600.00		*	Copayments capped at inpatient deducti
9195	Injection, udenyca 0.5 mg	K		\$124.783	.	\$24.96			*	
9196	Inj, trivisc 1 mg	K		\$8.795	.	\$1.76			*	
9197	Inj., fremanezumab-vfrm 1 mg	K		\$1.996	.	\$0.40			*	
9198	Inj andexxa, 10 mg	K		\$95.879	.	\$19.18			*	
9199	Injection, caplacizumab-yhdp	K		\$744.946	.	\$148.99			*	
9200	Inj, remdesivir, 1 mg	G		\$6.058	.	\$1.22			*	
9201	Rabies ig ht&sol human im/sc	K		\$234.090	.	\$46.82			*	
9202	Difelikefalin, esrd on dialy	K		\$0.214	.	\$0.05			*	
9203	Inj cyclophosphamd auromedic	G		\$3.869	.	\$0.78			*	
9204	Inj tisotu vedotin-tftv, 1mg	G		\$162.051	.	\$32.42			*	
9205	Inj lon tesirin-lpyl 0.075mg	G		\$196.449	.	\$39.29			*	
9206	Inj plasminogen tvmh 1mg	G		\$30.095	.	\$6.02			*	
9207	Injection, bortezomib, 0.1mg	K		\$3.031	.	\$0.61			*	
9208	Agalsidase beta injection	K		\$215.378	.	\$43.08			*	
9209	Laronidase injection	K		\$37.043	.	\$7.41			*	
9213	Inj. pemetrexed nos 10mg	K		\$7.933	.	\$1.59			*	
9214	Bevacizumab injection	K		\$73.579	.	\$14.72			*	
9215	Cetuximab injection	K		\$72.078	.	\$14.42			*	
9217	Leuprolide acetate suspnsion	K		\$165.863	.	\$33.18			*	
9225	Fluocinolone acetonide implt	K		\$322.381	.	\$64.48			*	
9229	Ibandronate sodium injection	K		\$29.314	.	\$5.87			*	
9230	Abatacept injection	K		\$43.271	.	\$8.66			*	
9233	Ranibizumab injection	K		\$236.583	.	\$47.32			*	
9234	Alglucosidase alfa injection	K		\$122.560	.	\$24.52			*	
9235	Panitumumab injection	K		\$149.709	.	\$29.42	\$29.42		*	Inflation-adjusted coinsurance
9236	Eculizumab injection	K		\$225.791	.	\$45.16			*	
9237	Inj, lanreotide acetate	K		\$54.182	.	\$10.84			*	
9239	Buprenorphine xr over 100 mg	K		\$1,886.367	.	\$377.28			*	
9240	Injection, ixabepilone	K		\$122.548	.	\$24.51			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9241	Inj sirolimus prot part 1 mg	G		\$107.606	.	\$21.53			*	
9243	Inj., treanda 1 mg	K		\$12.282	.	\$2.46			*	
9245	Romiplostim injection	K		\$95.468	.	\$18.83	\$18.83		*	Inflation-adjusted coinsurance
9251	C1 esterase inhibitor inj	K		\$60.727	.	\$12.15			*	
9252	Plerixafor injection	K		\$429.363	.	\$85.88			*	
9253	Temozolomide injection	K		\$10.410	.	\$2.09			*	
9255	Inj, invega sustenna, 1 mg	K		\$14.217	.	\$2.85			*	
9256	Dexamethasone intra implant	K		\$204.677	.	\$40.94			*	
9257	Inj., emicizumab-kxwh 0.5 mg	K		\$51.005	.	\$10.21			*	
9258	Telavancin injection	K		\$6.826	.	\$1.37			*	
9259	Pralatrexate injection	K		\$356.512	.	\$70.96	\$70.96		*	Inflation-adjusted coinsurance
9260	Ofatumumab injection	K		\$63.957	.	\$12.80			*	
9261	Ustekinumab sub cu inj, 1 mg	K		\$147.647	.	\$29.53			*	
9263	Ecallantide injection	K		\$530.720	.	\$106.15			*	
9264	Tocilizumab injection	K		\$5.910	.	\$1.19			*	
9269	C-1 esterase, berinert	K		\$64.445	.	\$12.89			*	
9270	Gammaplex IVIG	K		\$59.483	.	\$11.40	\$11.40		*	Inflation-adjusted coinsurance
9271	Velaglucerase alfa	K		\$367.181	.	\$73.44			*	
9272	Inj, denosumab	K		\$24.192	.	\$4.80	\$4.80		*	Inflation-adjusted coinsurance
9273	Sipuleucel-T auto CD54+	K		\$53,062.441	.	\$10,612.49	\$1,600.00		*	Copayments capped at inpatient deducti
9274	Crotalidae Poly Immune Fab	K		\$2,056.352	.	\$411.28			*	
9276	Cabazitaxel injection	K		\$206.032	.	\$41.21			*	
9278	Incobotulinumtoxin A	K		\$5.196	.	\$1.04			*	
9281	Injection, pegloticase	K		\$3,268.450	.	\$653.69			*	
9284	Ipilimumab injection	K		\$167.933	.	\$33.59			*	
9286	Belatacept injection	K		\$3.781	.	\$0.76			*	
9287	Brentuximab vedotin inj	K		\$221.964	.	\$43.27	\$43.27		*	Inflation-adjusted coinsurance
9289	Erwinaze injection	K		\$427.269	.	\$85.46			*	
9294	Inj, taliglucerase alfa 10 u	K		\$44.561	.	\$8.92			*	
9295	Injection, Carfilzomib, 1 mg	K		\$47.040	.	\$9.26	\$9.26		*	Inflation-adjusted coinsurance
9296	Inj, ziv-aflibercept, 1mg	K		\$6.812	.	\$1.37			*	
9297	Inj, Omacetaxine Mep, 0.01mg	K		\$4.007	.	\$0.76	\$0.76		*	Inflation-adjusted coinsurance
9298	Inj, Ocriplasmin, 0.125 mg	K		\$93.020	.	\$18.61			*	
9299	Inj. jivi 1 iu	K		\$2.354	.	\$0.48			*	
9300	Omalizumab injection	K		\$39.383	.	\$7.88			*	
9301	Aminolevulinic acid, 10% gel	K		\$1.649	.	\$0.33			*	
9302	Inj daunorubicin, cytarabine	K		\$227.232	.	\$45.45			*	
9304	Inj., cemiplimab-rwlc, 1 mg	K		\$26.923	.	\$5.39			*	
9305	Inj., lumoxiti, 0.01 mg	K		\$23.394	.	\$4.68			*	
9306	Inj., tildrakizumab, 1 mg	K		\$143.265	.	\$28.66			*	
9309	Inj. tagraxofusp-erzs 10 mcg	K		\$322.596	.	\$64.52			*	
9310	Inj., emapalumab-lzsg, 1 mg	K		\$393.723	.	\$78.75			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9311	Inj., omadacycline, 1 mg	K		\$3.683	.	\$0.74			*	
9312	Inj., ravulizumab-cwvz 10 mg	K		\$221.875	.	\$44.38			*	
9313	Inj. belrapzo/bendamustine	K		\$16.716	.	\$3.35			*	
9314	Inj. herceptin hylecta, 10mg	K		\$65.583	.	\$13.12			*	
9318	Inj hydroxyprogst capot nos	K		\$8.850	.	\$1.77			*	
9319	Somatropin injection	K		\$169.570	.	\$33.92				
9320	Carbidopa levodopa ent 100ml	K		\$226.831	.	\$45.37			*	
9323	Gallium ga-68 dotatoc	G		\$8.640	.	\$0.00		*		
9327	Inj. romosozumab-aqqg 1 mg	K		\$10.367	.	\$2.08			*	
9328	Inj., yutiq, 0.01 mg	K		\$529.269	.	\$105.86			*	
9329	Inj mvasi 10 mg	K		\$28.398	.	\$5.68			*	8% of reference add-on applied
9330	Inj., kanjinti, 10 mg	K		\$23.960	.	\$4.80			*	8% of reference add-on applied
9331	Inj, polatuzumab vedotin 1mg	K		\$121.252	.	\$24.26			*	
9333	Inj., brexanolone, 1 mg	K		\$72.393	.	\$14.48			*	
9336	Inj truxima 10 mg	K		\$39.791	.	\$7.96		*	*	8% of reference add-on applied
9337	Synjojoynt, inj., 1 mg	K		\$13.250	.	\$2.66		*	*	
9339	Iodine i-131 iobenguane 1mci	K		\$338.479	.	\$67.70			*	
9340	Inj, brolucizumab-dbl, 1 mg	K		\$319.946	.	\$63.99		*	*	
9341	Inj ogivri 10 mg	K		\$40.405	.	\$8.09		*	*	8% of reference add-on applied
9343	Inj givosiran 0.5 mg	K		\$112.486	.	\$22.50		*	*	
9345	Inj pegfilgrastim-bmez 0.5mg	K		\$30.049	.	\$6.01		*	*	8% of reference add-on applied
9346	Mometasone sinus sinuva	K		\$11.345	.	\$2.27		*	*	
9347	Inj luspatercept-aamt 0.25mg	K		\$39.181	.	\$7.84		*	*	
9348	Inj., zirabev, 10 mg	K		\$28.191	.	\$5.64		*	*	8% of reference add-on applied
9349	Inj hersuma 10 mg	G		\$29.870	.	\$5.98		*	*	8% of reference add-on applied
9350	Inj., trazimera, 10 mg	K		\$23.154	.	\$4.64		*	*	8% of reference add-on applied
9351	Inj bimatoprost itc imp 1mcg	G		\$206.406	.	\$41.29		*	*	
9352	Chloroquine injection	K		\$0.710	.	\$0.15			*	
9353	Inj fam-trastu deru-nxki 1mg	K		\$26.235	.	\$5.25		*	*	
9354	Inj recombin esperoct per iu	K		\$2.108	.	\$0.43		*	*	
9355	Inj. teprotumumab-trbw 10 mg	K		\$327.998	.	\$65.60		*	*	
9356	Inj golodirsen 10 mg	K		\$166.170	.	\$33.24		*	*	
9357	Inj. eptinezumab-jjmr 1 mg	K		\$17.443	.	\$3.49		*	*	
9358	Inj xipere 1 mg	G		\$48.486	.	\$9.70			*	
9359	Inj crizanlizumab-tmca 5mg	K		\$126.606	.	\$25.33		*	*	
9361	Inj. cetirizine hcl 0.5mg	K		\$15.065	.	\$3.02		*	*	
9362	Inj imip 4 cilas 4 releb 2mg	K		\$2.488	.	\$0.50		*	*	
9364	Inj enfort vedo-ejfv 0.25mg	K		\$33.818	.	\$6.65	\$6.65	*	*	Inflation-adjusted coinsurance
9367	Inj ruxience, 10 mg	K		\$27.509	.	\$5.51		*	*	8% of reference add-on applied
9370	Fluoroestradiol F 18	G		\$709.317	.	\$0.00		*		
9372	Inj. xembify, 100 mg	K		\$13.999	.	\$2.80			*	
9374	Mitomycin instillation	G		\$296.173	.	\$59.24		*	*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9375	Inj., evomela, 1 mg	K		\$16.441	.	\$3.29			*	
9376	Sacituzumab govitecan-hziy	G		\$33.315	.	\$6.67		*	*	
9377	Inj. isatuximab-irfc 10 mg	G		\$74.349	.	\$14.87		*	*	
9378	Daratumumab, hyaluronidase	G		\$49.120	.	\$9.83		*	*	
9381	Inj. avsola, 10 mg	G		\$28.334	.	\$5.67		*	*	8% of reference add-on applied
9382	Inj ontruzant 10 mg	G		\$46.927	.	\$9.39		*	*	8% of reference add-on applied
9383	Copper cu 64 dotatate diag	G		\$970.263	.	\$0.00		*	*	
9384	Inj belantamab mafodot blmf	G		\$46.780	.	\$9.36		*	*	
9385	Inj., tafasitamab-cxix	G		\$13.302	.	\$2.67		*	*	
9386	Inj. viltolarsen	G		\$58.845	.	\$11.77		*	*	
9387	Inj. infugem, 100 mg	G		\$40.280	.	\$7.82	\$7.82	*	*	Inflation-adjusted coinsurance
9388	Inj. fe derisomaltose 10 mg	G		\$20.613	.	\$4.13		*	*	
9389	Inj. lurbinectedin, 0.1 mg	G		\$197.177	.	\$39.44		*	*	
9390	Pertuzu, trastuzu, 10 mg	G		\$68.210	.	\$13.65		*	*	
9391	Brexucabtagene car pos t	G		\$449,440.000	.	\$89,888.00	\$1,600.00	*	*	Copayments capped at inpatient deducti
9392	Inj. asceniv	G		\$491.405	.	\$98.29		*	*	
9393	Inj codeine phosphate /30 mg	K		\$31.650	.	\$6.33			*	
9394	Inj. inebilizumab-cdon, 1 mg	G		\$472.303	.	\$94.47			*	
9395	Factor viia recomb sevenfact	G		\$2.013	.	\$0.41			*	
9396	Afamelanotide implant, 1 mg	K		\$2,873.329	.	\$574.67			*	
9397	Covid-19 Vaccine Admin Dose 1 of 2	S	0.4851	\$41.52	.	\$0.00				
9398	Covid-19 Vaccine Admin Dose 2 of 2, Single Dose Product or Additional Dose	S	0.4851	\$41.52	.	\$0.00				
9399	Covid-19 Vaccine Home Administration	S	0.4306	\$36.85	.	\$0.00				
9401	Bebtelovimab 175 mg	K		\$2,394.000	.	\$478.80			*	
9406	Inj, nyvepria	G		\$101.891	.	\$20.38			*	
9407	Inj. lumasiran, 0.5 mg	G		\$318.998	.	\$63.80			*	
9408	Inj. naxitamab-ggqk, 1 mg	G		\$579.649	.	\$115.93			*	
9409	Gallium ga-68 psma-11 ucsf	G		\$806.142	.	\$0.00				
9410	Gallium ga-68 psma-11, ucla	G		\$789.299	.	\$0.00				
9411	Inj. riabni, 10 mg	G		\$44.579	.	\$8.92			*	8% of reference add-on applied
9412	Injection, casimersen, 10 mg	G		\$166.201	.	\$33.25			*	
9413	Iisocabtagene car pos t	G		\$454,489.310	.	\$90,897.87	\$1,600.00		*	Copayments capped at inpatient deducti
9414	Inj, cabote rilpivir 2mg 3mg	G		\$21.842	.	\$4.37			*	
9415	Injection, trilaciclib, 1mg	G		\$5.102	.	\$1.03			*	
9416	Inj, evinacumab-dgnb, 5 mg	G		\$175.777	.	\$35.16			*	
9417	Inj, melphalan flufenami 1mg	G		\$503.500	.	\$100.70			*	
9418	Inj. margetuximab-cmkb, 5 mg	G		\$45.881	.	\$9.18			*	
9419	Inj fensolvi 0.25 mg	K		\$138.807	.	\$27.77			*	
9421	Inj, granisetron, xr, 0.1 mg	K		\$5.877	.	\$1.18			*	
9422	Idecabtagene vicleucel car	G		\$460,226.553	.	\$92,045.32	\$1,600.00		*	Copayments capped at inpatient deducti
9426	Inj, cefiderocol, 10 mg	G		\$2.163	.	\$0.44		*	*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9427	Injection, oritavancin 10 mg	G		\$41.734	.	\$8.35			*	
9428	Inj romidepsin non-lyo 0.1mg	G		\$33.905	.	\$6.79		*	*	
9429	Inj romidepsin lyophil 0.1mg	K		\$30.370	.	\$6.08			*	
9430	Piflu f-18, dia 1 millicurie	G		\$580.352	.	\$0.00				
9431	Inj, dostarlimab-gxly, 10 mg	G		\$226.925	.	\$45.39			*	
9432	Inj, amivantamab-vmjw	G		\$19.631	.	\$3.93	\$3.93		*	Inflation-adjusted coinsurance
9433	Inj aval alfa-nqpt 4mg	G		\$75.038	.	\$15.01			*	
9434	Inj anifrolumab-fnia 1mg	G		\$16.656	.	\$3.34			*	
9436	Inj pegfilgrast ex bio 0.5mg	K		\$85.710	.	\$17.15			*	
9437	Inj, aspara, rylaze, 0.1 mg	G		\$49.530	.	\$9.91			*	
9438	Injection, aducanumab-avwa, 2 mg	K		\$5.978	.	\$1.20			*	
9439	Inj, susvimo 0.1 mg	G		\$81.018	.	\$16.21			*	
9440	Instill, bupivac and meloxic	G		\$0.727	.	\$0.00			*	
9441	Inj ferric carboxymaltos 1mg	K		\$1.125	.	\$0.23			*	
9442	Inj. pemetrexed, 10 mg	G		\$64.476	.	\$12.90			*	
9443	Gallium illuccix 1 millicurie	G		\$996.400	.	\$0.00				
9444	Inj, sutimlimab-jome, 10 mg	G		\$17.754	.	\$3.52	\$3.52		*	Inflation-adjusted coinsurance
9445	Injection, ruconest	K		\$33.020	.	\$6.61			*	
9446	Inj, tebentafusp-tebn, 1 mcg	G		\$203.827	.	\$40.77			*	
9447	Inj, releuko 1 mcg	G		\$0.586	.	\$0.12			*	8% of reference add-on applied
9448	Oral netupitant, palonosetron	K		\$461.255	.	\$72.38	\$72.38		*	Inflation-adjusted coinsurance
9449	Injection, blinatumomab	K		\$144.683	.	\$27.97	\$27.97		*	Inflation-adjusted coinsurance
9450	Fluocinol acet intravit imp	K		\$490.947	.	\$98.19			*	
9451	Injection, peramivir	K		\$1.678	.	\$0.34			*	
9452	Inj ceftolozane tazobactam	K		\$7.540	.	\$1.51			*	
9453	Injection, nivolumab	K		\$30.457	.	\$6.10			*	
9454	Inj, pasireotide long acting	K		\$421.950	.	\$80.38	\$80.38		*	Inflation-adjusted coinsurance
9455	Injection, siltuximab	K		\$139.218	.	\$27.85			*	
9456	Injection, isavuconazonium	K		\$0.914	.	\$0.18			*	
9460	Injection, cangrelor	K		\$18.126	.	\$3.63			*	
9463	Inj., aprepitant, 1 mg	K		\$1.731	.	\$0.35			*	
9466	Inj., benralizumab, 1 mg	K		\$170.925	.	\$34.19			*	
9467	Inj rituximab, hyaluronidase	K		\$37.458	.	\$7.50			*	
9468	Factor ix recomb gly rebiny	K		\$4.414	.	\$0.89			*	
9469	Inj triamcinolone ace xr 1mg	K		\$17.114	.	\$3.43			*	
9470	Aripirazole lauroxil 1 mg	K		\$3.067	.	\$0.62			*	
9471	Hymovis injection 1 mg	K		\$17.019	.	\$3.41			*	
9472	Inj talimogene laherparepvec	K		\$66.054	.	\$12.93	\$12.93		*	Inflation-adjusted coinsurance
9473	Injection, mepolizumab, 1mg	K		\$29.747	.	\$5.95			*	
9474	Inj irinotecan liposome 1 mg	K		\$61.964	.	\$12.40			*	
9475	Injection, necitumumab, 1 mg	K		\$5.737	.	\$1.15			*	
9476	Injection, daratumumab 10 mg	K		\$61.783	.	\$12.36			*	

APC	Group Title	SI	Relative Weight	Payment Rate	National Unadjusted Copayment	Minimum Unadjusted Copayment	Adjusted Beneficiary Copayment	Drug and Device Pass-Through Expiration during Calendar Year	* Indicates a Change from the Previous Quarter	Note
9477	Injection, elotuzumab, 1mg	K		\$7.191	.	\$1.44			*	
9478	Inj sebelipase alfa 1 mg	K		\$537.810	.	\$107.57			*	
9479	Instill, ciprofloxacin otic	K		\$30.019	.	\$6.01			*	
9480	Injection trabectedin 0.1mg	K		\$337.279	.	\$67.46			*	
9481	Injection, reslizumab	K		\$10.198	.	\$2.04			*	
9482	Sotalol hydrochloride IV	K		\$20.737	.	\$4.15			*	
9483	Inj, atezolizumab,10 mg	K		\$82.678	.	\$16.54			*	
9487	Ustekinumab, iv inject,1 mg	K		\$12.594	.	\$2.52			*	
9488	Conivaptan hcl	K		\$47.240	.	\$9.45			*	
9489	Inj, nusinersen, 0.1mg	K		\$1,170.025	.	\$234.01			*	
9490	Inj, bezlotoxumab, 10 mg	K		\$39.853	.	\$7.98			*	
9491	Injection, avelumab, 10 mg	K		\$90.569	.	\$18.12			*	
9492	Inj., durvalumab, 10 mg	K		\$79.763	.	\$15.96			*	
9493	Injection, edaravone, 1 mg	K		\$21.402	.	\$4.29			*	
9494	Injection, ocrelizumab	K		\$61.417	.	\$12.29			*	
9495	Gemtuzumab ozogamicin inj	K		\$221.843	.	\$44.37			*	
9496	Inj, faricimab-svoa, 0.1mg	G		\$37.089	.	\$7.42			*	
9498	Ciltacabtagene car-pos t	G		\$492,900.000	.	\$98,580.00	\$1,600.00		*	Copayments capped at inpatient deducti
9499	Adenovirus vaccine type 4	K		\$357.980	.	\$71.60			*	
9500	Platelets, irradiated	R	1.6802	\$143.80	.	\$28.76				
9501	Platelet pheres leukoreduced	R	5.6746	\$485.66	.	\$97.14				
9502	Platelet pheresis irradiated	R	7.2055	\$616.68	.	\$123.34				
9503	Fr frz plasma donor retested	R	0.6396	\$54.74	.	\$10.95				
9504	RBC deglycerolized	R	4.8283	\$413.23	.	\$82.65				
9505	RBC irradiated	R	2.2924	\$196.20	.	\$39.24				
9507	Platelets, pheresis	R	3.9022	\$333.97	.	\$66.80				
9508	Plasma 1 donor frz w/in 8 hr	R	0.9986	\$85.47	.	\$17.10				
9509	Frozen plasma, pooled, sd	R	1.0870	\$93.03	.	\$18.61				
9510	Whole blood for transfusion	R	2.6595	\$227.61	.	\$45.53				
9511	Cryoprecipitate each unit	R	0.8692	\$74.39	.	\$14.88				
9512	RBC leukocytes reduced	R	2.2108	\$189.21	.	\$37.85				
9513	Plasma, frz between 8-24hour	R	0.8903	\$76.20	.	\$15.24				
9514	Plasma protein fract,5%,50ml	R	0.0928	\$7.94	.	\$1.59				
9515	Platelets, each unit	R	0.9024	\$77.23	.	\$15.45				
9516	Plaelet rich plasma unit	R	5.2027	\$445.27	.	\$89.06				
9517	Red blood cells unit	R	1.5835	\$135.52	.	\$27.11				
9518	Washed red blood cells unit	R	4.6244	\$395.78	.	\$79.16				
9519	Plasmaprotein fract,5%,250ml	R	1.8503	\$158.36	.	\$31.68				
9520	Blood split unit	R	1.6247	\$139.05	.	\$27.81				
9521	Platelets leukoreduced irrada	R	3.1356	\$268.36	.	\$53.68				
9522	RBC leukoreduced irradiated	R	3.0276	\$259.12	.	\$51.83				
9523	Cryoprecipitatereducedplasma	R	0.8050	\$68.90	.	\$13.78				

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 23

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 24

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 25

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 26

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 27

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 28

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 29

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 30

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 31

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 32

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 33

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 34

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 35

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 36

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 37

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 38

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 39

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 40

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 41

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 42

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 43

[illegible]

SUPPLEMENT 3

July 2023 OPPS Addendum A (Updated 8/1/23)

3 - 44

[illegible]